Current Treatment for Cervical Cancer: An Update

Sombeer       Sharma; Aakash       Deep; Arun    K.    Sharma

doi:10.2174/1871520620666200224093301

Abstract

Cervical cancer is the leading gynecologic health problem which is considered as the 4th most widespread tumour in women. The prevalence of this fatal ailment is emerging gradually across the globe as about 18.1 million new cancer cases have been reported in 2018. The predominance of cervical cancer has been significantly found in low and middle-income countries as cervical cancer ranks fourth for both incidence and mortality, conversely, there are no effective screening systems available. This mortal state is certainly influenced by exposure of human papillomavirus, dysregulation of caspase enzyme, elevated expression of Inhibitor Apoptotic Protein (IAP), overexpression of Vascular Endothelial Growth Factors (VEGF), active/passive smoking, and dysfunction of the immune system. Generally, the clinical trial on pipeline drugs leads to the development of some promising new therapies that are more effective than standard approaches and often unavailable outside of the clinical setting. Indeed, several biological interventions that can modulate the pathological cascade of cervical cancer are still under investigation. Thus, there is a need to further summarise the promising therapies for cervical cancer as we have accomplished in HER2-positive breast cancer by targeting HER2 therapies and immune checkpoint inhibitors in melanoma. The present report revealed the pharmacokinetic/ pharmacodynamics aspects of various pipeline drugs that are promising for the treatment of cervical cancer. Moreover, the study revealed the possible mechanism, adverse drug reaction, combined therapy and pleiotropic action of these under investigational drugs, which can further improve the therapeutic efficacy and restrict the imaginable harmful effects.

Keywords: Cervical cancer, clinical trial, pipeline drug for cervical cancer, pharmacokinetics, quality of life, molecular biology.

« Previous Next »

Graphical Abstract

[1] 
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.,  2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492 ] [PMID:  30207593] 
[2] 
Melaku, Y.A.; Appleton, S.L.; Gill, T.K.; Ogbo, F.A.; Buckley, E.; Shi, Z.; Driscoll, T.; Adams, R.; Cowie, B.C.; Fitzmaurice, C. Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990-2015: Findings from the Global Burden of Disease Study 2015. Cancer Epidemiol.,  2018, 52, 43-54.
[http://dx.doi.org/10.1016/j.canep.2017.11.007 ] [PMID:  29216565] 
[3] 
Plummer, M.; de Martel, C.; Vignat, J.; Ferlay, J.; Bray, F.; Franceschi, S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob. Health,  2016, 4(9), e609-e616.
[http://dx.doi.org/10.1016/S2214-109X(16)30143-7] [PMID:  27470177] 
[4] 
Lei, J.; Ploner, A.; Lagheden, C.; Eklund, C.; Nordqvist Kleppe, S.; Andrae, B.; Elfström, K.M.; Dillner, J.; Sparén, P.; Sundström, K. High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. PLoS Med.,  2018, 15(10), e1002666.
[http://dx.doi.org/10.1371/journal.pmed.1002666] [PMID:  30273338] 
[5] 
Bosch, F.X.; Lorincz, A.; Muñoz, N.; Meijer, C.J.; Shah, K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.,  2002, 55(4), 244-265.
[http://dx.doi.org/10.1136/jcp.55.4.244 ] [PMID:  11919208] 
[6] 
Anderson, L.; Henderson, C.; Adachi, Y. Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol. Cell. Biol.,  2001, 21(5), 1719-1729.
[http://dx.doi.org/10.1128/MCB.21.5.1719-1729.2001 ] [PMID:  11238909] 
[7] 
Shibata, T.; Lieblong, B.J.; Sasagawa, T.; Nakagawa, M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat. Rev.,  2019, 78, 8-16.
[http://dx.doi.org/10.1016/j.ctrv.2019.07.001 ] [PMID:  31302573] 
[8] 
Ren, G.; Zhao, Y.P.; Yang, L.; Fu, C.X. Anti-proliferative effect of clitocine from the mushroom Leucopaxillus giganteus on human cervical cancer HeLa cells by inducing apoptosis. Cancer Lett.,  2008, 262(2), 190-200.
[http://dx.doi.org/10.1016/j.canlet.2007.12.013 ] [PMID:  18222036] 
[9] 
Park, I.; Park, K.K.; Park, J.H.Y.; Chung, W.Y. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett.,  2009, 277(2), 174-181.
[http://dx.doi.org/10.1016/j.canlet.2008.12.005 ] [PMID:  19167809] 
[10] 
Simon, A.E.; Waller, J.; Robb, K.; Wardle, J. Patient delay in presentation of possible cancer symptoms: The contribution of knowledge and attitudes in a population sample from the United Kingdom. Cancer Epidemiol. Biomarkers Prev.,  2010, 19(9), 2272-2277.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0219] [PMID:  20660602] 
[11] 
Baust, J.G.; Gage, A.A. The molecular basis of cryosurgery. BJU Int.,  2005, 95(9), 1187-1191.
[http://dx.doi.org/10.1111/j.1464-410X.2005.05502.x ] [PMID:  15892798] 
[12] 
Moon, J.Y.; Song, I.C.; Ko, Y.B.; Lee, H.J. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer. Medicine (Baltimore), 2018,  97, 0340.
[13] 
Crafton, S.M.; Salani, R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin. Ther.,  2016, 38(3), 449-458.
[http://dx.doi.org/10.1016/j.clinthera.2016.02.007 ] [PMID:  26926322] 
[14] 
National cancer institute. Treatment Clinical Trials for Cervical Cancer., https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/cervicalcancer/  [Accessed on June 09, 2019].
[15] 

Gene Therapy Net Risks and Benefits of Clinical Trials., http://www.genetherapynet.com/risks-and-benefits-of-clinical-trials.html [Accessed on June 09, 2019].
[16] 

                        Cancer.Net. Cervical Cancer: About Clinical Trials.,
                     https://www.cancer.net/cancertypes/cervical-cancer/about-clinical-trials [Accessed on June 09, 2019].
[17] 

ClinicalTrials.gov Nivolumab and Ipilimumab in Treating Patients With Rare Tumors., https://clinicaltrials.gov/ct2/show/NCT02834013 [Accessed on June 09, 2019].
[18] 
Ready, N.; Hellmann, M.D.; Awad, M.M.; Otterson, G.A.; Gutierrez, M.; Gainor, J.F.; Borghaei, H.; Jolivet, J.; Horn, L.; Mates, M.; Brahmer, J.; Rabinowitz, I.; Reddy, P.S.; Chesney, J.; Orcutt, J.; Spigel, D.R.; Reck, M.; O’Byrne, K.J.; Paz-Ares, L.; Hu, W.; Zerba, K.; Li, X.; Lestini, B.; Geese, W.J.; Szustakowski, J.D.; Green, G.; Chang, H.; Ramalingam, S.S. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol.,  2019, 37(12), 992-1000.
[http://dx.doi.org/10.1200/JCO.18.01042 ] [PMID:  30785829] 
[19] 
Lacouture, M.E.; Wolchok, J.D.; Yosipovitch, G.; Kähler, K.C.; Busam, K.J.; Hauschild, A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol.,  2014, 71(1), 161-169.
[http://dx.doi.org/10.1016/j.jaad.2014.02.035 ] [PMID:  24767731] 
[20] 
Motzer, R.J.; Rini, B.I.; McDermott, D.F.; Redman, B.G.; Kuzel, T.M.; Harrison, M.R.; Vaishampayan, U.N.; Drabkin, H.A.; George, S.; Logan, T.F.; Margolin, K.A.; Plimack, E.R.; Lambert, A.M.; Waxman, I.M.; Hammers, H.J. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol.,  2015, 33(13), 1430-1437.
[http://dx.doi.org/10.1200/JCO.2014.59.0703 ] [PMID:  25452452] 
[21] 
Trinh, V.A.; Hagen, B. Ipilimumab for advanced melanoma: A pharmacologic perspective. J. Oncol. Pharm. Pract.,  2013, 19(3), 195-201.
[http://dx.doi.org/10.1177/1078155212459100 ] [PMID:  23047236] 
[22] 
Guo, L.; Zhang, H.; Chen, B. Nivolumab as Programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J. Cancer,  2017, 8(3), 410-416.
[http://dx.doi.org/10.7150/jca.17144 ] [PMID:  28261342] 
[23] 

National Cancer Institute Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy., https://www.cancer.gov/about-cancer/treatment/clinicaltrials/search/v?id=NCI-2011-01973&r=1 [Accessed on June 09, 2019].
[24] 
Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol.,  2014, 740, 364-378.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025 ] [PMID:  25058905] 
[25] 
Sousa, G.F.; Wlodarczyk, S.R.; Monteiro, G. Carboplatin: Molecular mechanisms of action associated with chemoresistance. Braz. J. Pharm. Sci.,  2014, 50, 693-701.
[http://dx.doi.org/10.1590/S1984-82502014000400004] 
[26] 
Wanderley, C.W.; Colón, D.F.; Luiz, J.P.M.; Oliveira, F.F.; Viacava, P.R.; Leite, C.A.; Pereira, J.A.; Silva, C.M.; Silva, C.R.; Silva, R.L.; Speck-Hernandez, C.A.; Mota, J.M.; Alves-Filho, J.C.; Lima-Junior, R.C.; Cunha, T.M.; Cunha, F.Q. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res.,  2018, 78(20), 5891-5900.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-3480 ] [PMID:  30104241] 
[27] 
Lee, J.M.; Peer, C.J.; Yu, M.; Amable, L.; Gordon, N.; Annunziata, C.M.; Houston, N.; Goey, A.K.; Sissung, T.M.; Parker, B.; Minasian, L.; Chiou, V.L.; Murphy, R.F.; Widemann, B.C.; Figg, W.D.; Kohn, E.C. Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women’s cancer. Clin. Cancer Res.,  2017, 23(6), 1397-1406.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1546 ] [PMID:  27663600] 
[28] 
Andey, T.; Sudhakar, G.; Marepally, S.; Patel, A.; Banerjee, R.; Singh, M. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: Pharmacokinetic and efficacy evaluation. Mol. Pharm.,  2015, 12(4), 1105-1120.
[http://dx.doi.org/10.1021/mp5008629 ] [PMID:  25661724] 
[29] 
Mielke, S.; Sparreboom, A.; Behringer, D.; Mross, K. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res.,  2005, 25(6C), 4423-4427.
[PMID:  16334120] 
[30] 
Jiko, M.; Yano, I.; Sato, E.; Takahashi, K.; Motohashi, H.; Masuda, S.; Okuda, M.; Ito, N.; Nakamura, E.; Segawa, T.; Kamoto, T.; Ogawa, O.; Inui, K. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol.,  2007, 12(4), 284-290.
[http://dx.doi.org/10.1007/s10147-007-0681-y ] [PMID:  17701008] 
[31] 
National Cancer Institute. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475- 158/KEYNOTE-158)., https://www.cancer.gov/aboutcancer/treatment/clinical-trials/search/v?id=NCI-2015  [Accessed on June 09, 2019].
[32] 
Drug Information Portal - U.S. National Library of Medicine Pembrolizumab. https://druginfo.nlm.nih.gov/drugportal/name/Pembrolizumab [Accessed on June 09, 2019].
[33] 
Joshi, S.S.; Maron, S.B.; Catenacci, D.V. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol.,  2018, 14(5), 417-430.
[http://dx.doi.org/10.2217/fon-2017-0436 ] [PMID:  29094609] 
[34] 
Lindauer, A.; Valiathan, C.R.; Mehta, K.; Sriram, V.; de Greef, R.; Elassaiss-Schaap, J.; de Alwis, D.P.; Elassaiss, S.J.; de Alwis, D.P. Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose‐ range selection of the anti–PD‐ 1 antibody pembrolizumab. CPT Pharmacometrics Syst. Pharmacol.,  2017, 6(1), 11-20.
[http://dx.doi.org/10.1002/psp4.12130 ] [PMID:  27863176] 
[35] 
Combination Pembrolizumab,  Chemotherapy and Bevacizumab in Patients With Cervical Cancer., https://clinicaltrials.gov/ct2/show/NCT03367871? term=cervix+cancer&recrs=a&cond=Cervical+Cancer&gndr=Female&age=1 [Accessed on June 09, 2019].
[36] 
Drug Information Portal - U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/Bevacizumab  [Accessed on June 09, 2019].
[37] 
Hara, M.; Nagasaki, T.; Shiga, K.; Takahashi, H.; Takeyama, H. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: The effect on the outcome and the response to chemotherapy plus bevacizumab. Surg. Today,  2017, 47(4), 483-489.
[http://dx.doi.org/10.1007/s00595-016-1404-7 ] [PMID:  27549777] 
[38] 
Moen, M.D. Bevacizumab: In previously treated glioblastoma. Drugs,  2010, 70(2), 181-189.
[http://dx.doi.org/10.2165/11203890-000000000-00000 ] [PMID:  20108991] 
[39] 

National Cancer Institute.  A Trial of Tisotumab Vedotin in Cervical Cancer., https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018 [Accessed on June 09, 2019]. 
[40] 
Genetics, S. Tisotumab vedotin., https://www.seattlegenetics.com/pipeline/[Accessed on June 09, 2019]. 
[41] 
Chu, A.J. Tissue factor, blood coagulation, and beyond: An overview. Int. J. Inflamm.,  2011, 2011, 367284.
[http://dx.doi.org/10.4061/2011/367284] [PMID:  21941675] 
[42] 
Cocco, E.; Varughese, J.; Buza, N.; Bellone, S.; Glasgow, M.; Bellone, M.; Todeschini, P.; Carrara, L.; Silasi, D.A.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Lockwood, C.J.; Santin, A.D. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer,  2011, 11, 263.
[http://dx.doi.org/10.1186/1471-2407-11-263 ] [PMID:  21693061] 
[43] 
Breij, E.C.; de Goeij, B.E.; Verploegen, S.; Schuurhuis, D.H.; Amirkhosravi, A.; Francis, J.; Miller, V.B.; Houtkamp, M.; Bleeker, W.K.; Satijn, D.; Parren, P.W. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res.,  2014, 74(4), 1214-1226.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2440] [PMID:  24371232] 
[44] 
de Bono, J.S.; Concin, N.; Hong, D.S.; Thistlethwaite, F.C.; Machiels, J.P.; Arkenau, H.T.; Plummer, R.; Jones, R.H.; Nielsen, D.; Windfeld, K.; Ghatta, S.; Slomovitz, B.M.; Spicer, J.F.; Yachnin, J.; Ang, J.E.; Mau-Sørensen, P.M.; Forster, M.D.; Collins, D.; Dean, E.; Rangwala, R.A.; Lassen, U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1-2 trial. Lancet Oncol.,  2019, 20(3), 383-393.
[http://dx.doi.org/10.1016/S1470-2045(18)30859-3] [PMID:  30745090] 
[45] 
Study of REGN2810 in Adults With Cervical Cancer., https://clinicaltrials.gov/ct2/show/NCT03257267 [Accessed on June 09, 2019].
[46] 
Tewari, K.S.; Vergote, I.; Oaknin, A.; Alvarez, E.; Chase, D.M.; Gaillard, S.; Lheureux, S.; Rischin, D.; Santin, A.; Feng, M.; Matthew, M.M.; Fury, G.; Lowy, I.; Monk, B.J. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator’s choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. J. Clin. Oncol.,  2018, 36, 15.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5600] 
[47] 
Adhisivam, B.; Vishnu Bhat, B.; Rao, K.; Kingsley, S.M.; Plakkal, N.; Palanivel, C. Effect of Holder pasteurization on macronutrients and immunoglobulin profile of pooled donor human milk. J. Matern. Fetal Neonatal Med.,  2019, 32(18), 3016-3019.
[http://dx.doi.org/10.1080/14767058.2018.1455089 ] [PMID:  29587541] 
[48] 
DrugBank. Cemiplimab. https://www.drugbank.ca/drugs/DB14707 [Accessed on June 09, 2019].
[49] 

ClinicalTrials.gov. Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy., https://clinicaltrials.gov/ct2/show/NCT01926821?term=cervix+cancer&recrs=a&cond=Cervi  [Accessed on June 09, 2019].
[50] 
 National centre for advancing translational sciences-U.S. Department of health and human services. SIZOFIRAN., https://drugs.ncats.io/substance/7F763NNC9X  [Accessed on June 09, 2019].
[51] 
Tanji, S.; Akima, K.; Horiba, M.; Amemiya, K.; Aimoto, T. Studies on metabolism and disposition of Sizofiran (SPG), an anti-tumor polysaccharide. III. Degradation and excretion of SPG in rats. Yakugaku Zasshi,  1990, 110(11), 869-875.
[http://dx.doi.org/10.1248/yakushi1947.110.11_869 ] [PMID:  2127945] 
[52] 
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent with Pelvic Radiation for Locally Advanced Cervical Cancer (IIIVA)., https://clinicaltrials.gov/ct2/show/NCT02363829?term=cervix+cancer&recrs=a&cond=Cervi [Accessed on June 09, 2019].
[53] 
Maksimovic-Ivanic, D.; Fagone, P.; McCubrey, J.; Bendtzen, K.; Mijatovic, S.; Nicoletti, F. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? Int. J. Cancer,  2017, 140(8), 1713-1726.
[http://dx.doi.org/10.1002/ijc.30529 ] [PMID:  27870005] 
[54] 
Kattel, K.; Evande, R.; Tan, C.; Mondal, G.; Grem, J.L.; Mahato, R.I. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br. J. Clin. Pharmacol.,  2015, 80(2), 267-275.
[http://dx.doi.org/10.1111/bcp.12620 ] [PMID:  25752914] 
[55] 

ClinicalTrials.gov Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium., https://clinicaltrials.gov/ct2/show/NCT03476798?term=cervix+ [Accessed on June 09, 2019].
[56] 
Syed, Y.Y. Rucaparib: First global approval. Drugs,  2017, 77(5), 585-592.
[http://dx.doi.org/10.1007/s40265-017-0716-2 ] [PMID:  28247266] 
[57] 
Raineri, A.; Prodomini, S.; Fasoli, S.; Gotte, G.; Menegazzi, M. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells. Biochem. Pharmacol.,  2019, 167, 173-181.
[http://dx.doi.org/10.1016/j.bcp.2019.06.006 ] [PMID:  31185226] 
[58] 
Mann, M.; Kumar, S.; Sharma, A.; Chauhan, S.S.; Bhatla, N.; Kumar, S.; Bakhshi, S.; Gupta, R.; Kumar, L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget,  2019, 10(42), 4262-4275.
[http://dx.doi.org/10.18632/oncotarget.27101 ] [PMID:  31303961] 
[59] 
Prasad, C.B.; Prasad, S.B.; Yadav, S.S.; Pandey, L.K.; Singh, S.; Pradhan, S.; Narayan, G. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci. Rep.,  2017, 7(1), 12876.
[http://dx.doi.org/10.1038/s41598-017-13232-3 ] [PMID:  28993682] 
[60] 
Thaker, P.H.; Salani, R.; Brady, W.E.; Lankes, H.A.; Cohn, D.E.; Mutch, D.G.; Mannel, R.S.; Bell-McGuinn, K.M.; Di Silvestro, P.A.; Jelovac, D.; Carter, J.S.; Duan, W.; Resnick, K.E.; Dizon, D.S.; Aghajanian, C.; Fracasso, P.M. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann. Oncol.,  2017, 28(3), 505-511.
[http://dx.doi.org/10.1093/annonc/mdw635 ] [PMID:  27998970] 
[61] 

ClinicalTrials.gov. Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer., https://clinicaltrials.gov/ct2/show/NCT01676818  [Accessed on June 09, 2019].
[62] 
Cortes, J.; Schöffski, P.; Littlefield, B.A. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treat. Rev.,  2018, 70, 190-198.
[http://dx.doi.org/10.1016/j.ctrv.2018.08.008 ] [PMID:  30243063] 
[63] 
Jain, S.; Vahdat, L.T. Eribulin mesylate. Clin. Cancer Res.,  2011, 17(21), 6615-6622.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1807 ] [PMID:  21859830] 
[64] 
Schwab, K.S.; Kristiansen, G.; Isaak, A.; Held, S.E.A.; Heine, A.; Brossart, P. Long term remission and cardiac toxicity of a combination of ipilimumab and nivolumab in a patient with metastatic head and neck carcinoma after progression following nivolumab monotherapy. Front. Oncol.,  2019, 9, 403.
[http://dx.doi.org/10.3389/fonc.2019.00403 ] [PMID:  31157170] 
[65] 
Rozeman, E.A.; Menzies, A.M.; van Akkooi, A.C.J.; Adhikari, C.; Bierman, C.; van de Wiel, B.A.; Scolyer, R.A.; Krijgsman, O.; Sikorska, K.; Eriksson, H.; Broeks, A.; van Thienen, J.V.; Guminski, A.D.; Acosta, A.T.; Ter Meulen, S.; Koenen, A.M.; Bosch, L.J.W.; Shannon, K.; Pronk, L.M.; Gonzalez, M.; Ch’ng, S.; Grijpink-Ongering, L.G.; Stretch, J.; Heijmink, S.; van Tinteren, H.; Haanen, J.B.A.G.; Nieweg, O.E.; Klop, W.M.C.; Zuur, C.L.; Saw, R.P.M.; van Houdt, W.J.; Peeper, D.S.; Spillane, A.J.; Hansson, J.; Schumacher, T.N.; Long, G.V.; Blank, C.U. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. Lancet Oncol.,  2019, 20(7), 948-960.
[http://dx.doi.org/10.1016/S1470-2045(19)30151-2 ] [PMID:  31160251] 
[66] 
Chang, Q.; Zhang, Y.; Xu, J.; Zhong, R.; Qiang, H.; Zhang, B.; Han, B.; Qian, J.; Chu, T. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China. Thorac. Cancer,  2019, 10(5), 1043-1050.
[http://dx.doi.org/10.1111/1759-7714.13025 ] [PMID:  30900826] 
[67] 
Nomura, H.; Aoki, D.; Michimae, H.; Mizuno, M.; Nakai, H.; Arai, M.; Sasagawa, M.; Ushijima, K.; Sugiyama, T.; Saito, M.; Tokunaga, H.; Matoda, M.; Nakanishi, T.; Watanabe, Y.; Takahashi, F.; Saito, T.; Yaegashi, N. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: A randomized clinical trial. JAMA Oncol.,  2019, 5(6), 833-840.
[http://dx.doi.org/10.1001/jamaoncol.2019.0001 ] [PMID:  30896757] 
[68] 
Song, D.; Kong, W.; Zhang, T.; Han, C.; Liu, T.; Jiao, S.; Chen, J. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer. J. Obstet. Gynaecol.,  2019, 39(3), 389-394.
[http://dx.doi.org/10.1080/01443615.2017.1416595] [PMID:  30663464] 
[69] 
Kim, R.; Keam, B.; Hahn, S.; Ock, C.Y.; Kim, M.; Kim, T.M.; Kim, D.W.; Heo, D.S. First-line pembrolizumab versus pembroLIZUMAB plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: A systematic review and network meta-analysis. Clin. Lung Cancer,  2019, 20(5), 331-338.e4.
[http://dx.doi.org/10.1016/j.cllc.2019.05.009 ] [PMID:  31164319] 
[70] 
Quagliariello, V.; Passariello, M.; Coppola, C.; Rea, D.; Barbieri, A.; Scherillo, M.; Monti, M.G.; Iaffaioli, R.V.; De Laurentiis, M.; Ascierto, P.A.; Botti, G.; De Lorenzo, C.; Maurea, N. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. Int. J. Cardiol.,  2019, 292, 171-179.
[http://dx.doi.org/10.1016/j.ijcard.2019.05.028 ] [PMID:  31160077] 
[71] 
Tokuyasu, H.; Takeda, K.; Kawasaki, Y.; Sakaguchi, Y.; Isowa, N.; Shimizu, E.; Ueda, Y. High plasma concentration of beta-D-glucan after administration of sizofiran for cervical cancer. Int. J. Gen. Med.,  2010, 3, 273-277.
[PMID:  21042427] 
[72] 
Davis, M.A.; Delaney, J.R.; Patel, C.B.; Storgard, R.; Stupack, D.G. Nelfinavir is effective against human cervical cancer cells in vivo: A potential treatment modality in resource-limited settings. Drug Des. Devel. Ther.,  2016, 10, 1837-1846.
[PMID:  27330277] 
[73] 
Xia, C.; He, Z.; Liang, S.; Chen, R.; Xu, W.; Yang, J.; Xiao, G.; Jiang, S. Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice. Eur. J. Pharmacol.,  2019, 848, 62-69.
[http://dx.doi.org/10.1016/j.ejphar.2019.01.045 ] [PMID:  30695683] 
[74] 
Tang, M.; Liu, Q.; Zhou, L.; Chen, L.; Yang, X.; Yu, J.; Wang, Y.; Qiu, H. The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer. Invest. New Drugs,  2019, 37(1), 65-75.
[http://dx.doi.org/10.1007/s10637-018-0616-7 ] [PMID:  29872938] 
[75] 
Perez-Garcia, J.M.; Cortes, J. The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin. Drug Saf.,  2019, 18(5), 347-355.
[http://dx.doi.org/10.1080/14740338.2019.1608946 ] [PMID:  31107111] 

Rights & Permissions Print Cite

Article Metrics

57

8

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871520620666200224093301	Print ISSN 1871-5206
Publisher Name Bentham Science Publisher	Online ISSN 1875-5992

Anti-Cancer Agents in Medicinal Chemistry

Current Treatment for Cervical Cancer: An Update

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract